Syndax Pharmaceuticals Inc (SNDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $850.77M
Last updated: Nov 17, 2026 at 11:06 AM ET
Syndax Pharmaceuticals Inc (SNDX) Earnings: Report Dates and Results
Syndax Pharmaceuticals (SNDX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Syndax Pharmaceuticals reported EPS of -$0.55, below the -$0.52 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SNDX has an expected report date of Feb 24, 2027.
SNDX Earnings Call
The latest SNDX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, SNDX beat 27, missed 10 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $83.30M, up 81.6% from $45.87M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.55 | -$0.52 | -$0.58 - -$0.38 | -5.77% | Miss | N/A | 11 | 0 up, 1 down | Nov 2, 2026 | $83.30M |
| Jun 30, 2026 | -$0.55 | -$0.45 | -$0.67 - -$0.33 | -22.22% | Miss | N/A | 11 | N/A | Aug 4, 2026 | $72.79M |
| Mar 31, 2026 | -$0.48 | -$0.59 | -$0.83 - -$0.39 | +18.64% | Beat | N/A | 11 | 1 up, 1 down | Apr 30, 2026 | $64.86M |
| Dec 31, 2025 | -$0.78 | -$0.64 | -$0.82 - -$0.06 | -21.88% | Miss | N/A | 12 | 5 up, 1 down | Feb 26, 2026 | $68.48M |
| Sep 30, 2025 | -$0.70 | -$0.71 | -$0.97 - -$0.54 | +1.41% | Beat | N/A | 12 | 0 up, 2 down | Nov 3, 2025 | $45.87M |
| Jun 30, 2025 | -$0.83 | -$1.01 | -$1.12 - -$0.85 | +17.82% | Beat | N/A | 11 | 1 up, 1 down | Aug 4, 2025 | $37.96M |
| Mar 31, 2025 | -$0.98 | -$1.27 | -$4.08 - -$0.59 | +22.83% | Beat | N/A | 11 | 1 up, 1 down | May 5, 2025 | $20.04M |
| Dec 31, 2024 | -$1.10 | -$0.23 | -$1.27 - $3.49 | -380.56% | Miss | N/A | 13 | 1 up, 1 down | Mar 3, 2025 | $7.68M |
| Sep 30, 2024 | -$0.98 | -$1.06 | -$1.26 - -$0.82 | +7.55% | Beat | N/A | 12 | 0 up, 0 down | Nov 5, 2024 | $12.50M |
| Jun 30, 2024 | -$0.80 | -$0.91 | -$0.97 - -$0.87 | +12.09% | Beat | N/A | 12 | 0 up, 0 down | Aug 1, 2024 | $3.50M |
| Mar 31, 2024 | -$0.85 | -$0.98 | -$1.11 - -$0.90 | +13.27% | Beat | N/A | 11 | 2 up, 0 down | May 8, 2024 | N/A |
| Dec 31, 2023 | -$1.00 | -$0.97 | -$1.15 - -$0.84 | -3.09% | Miss | N/A | 10 | 1 up, 0 down | Feb 27, 2024 | $536000 |
| Sep 30, 2023 | -$0.73 | -$0.80 | -$0.87 - -$0.75 | +8.75% | Beat | N/A | 10 | 0 up, 0 down | Nov 2, 2023 | N/A |
| Jun 30, 2023 | -$0.64 | -$0.75 | -$0.81 - -$0.61 | +14.67% | Beat | N/A | 9 | 0 up, 0 down | Aug 3, 2023 | N/A |
| Mar 31, 2023 | -$0.59 | -$0.61 | -$0.65 - -$0.56 | +3.28% | Beat | N/A | 7 | 0 up, 0 down | May 8, 2023 | N/A |
| Dec 31, 2022 | -$0.62 | -$0.65 | -$0.71 - -$0.58 | +4.62% | Beat | -134.3% | 8 | 0 up, 0 down | Feb 28, 2023 | N/A |
| Sep 30, 2022 | -$0.58 | -$0.63 | -$0.66 - -$0.60 | +7.94% | Beat | N/A | 6 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$0.62 | -$0.62 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | N/A |
| Mar 31, 2022 | -$0.63 | -$0.68 | -$0.68 - -$0.51 | +7.35% | Beat | N/A | 6 | 1 up, 0 down | May 9, 2022 | N/A |
| Dec 31, 2021 | $1.81 | $0.28 | -$0.74 - $2.51 | +546.43% | Beat | N/A | 6 | 0 up, 0 down | Mar 1, 2022 | $126.58M |
| Sep 30, 2021 | -$0.40 | -$0.57 | -$0.65 - $1.54 | +29.82% | Beat | N/A | 6 | N/A | Nov 15, 2021 | $12.38M |
| Jun 30, 2021 | -$0.44 | -$0.73 | -$0.77 - -$0.64 | +39.73% | Beat | N/A | 6 | N/A | Aug 9, 2021 | $379000 |
| Mar 31, 2021 | -$0.54 | -$0.64 | -$0.71 - -$0.58 | +15.63% | Beat | N/A | 6 | N/A | May 11, 2021 | $379000 |
| Dec 31, 2020 | -$0.44 | -$0.49 | -$0.54 - -$0.36 | +10.20% | Beat | N/A | 8 | N/A | Mar 8, 2021 | $380000 |
| Sep 30, 2020 | -$0.46 | -$0.43 | -$0.49 - -$0.38 | -6.98% | Miss | N/A | 5 | N/A | Nov 2, 2020 | $379000 |
| Jun 30, 2020 | -$0.42 | -$0.44 | -$0.53 - -$0.35 | +4.55% | Beat | N/A | 6 | N/A | Aug 6, 2020 | $379000 |
| Mar 31, 2020 | -$0.56 | -$0.51 | -$0.60 - -$0.46 | -9.80% | Miss | N/A | 8 | N/A | May 7, 2020 | $379000 |
| Dec 31, 2019 | -$0.44 | -$0.43 | -$0.52 - -$0.32 | -2.33% | Miss | N/A | 7 | N/A | Mar 3, 2020 | $380000 |
| Sep 30, 2019 | -$0.41 | -$0.48 | -$0.54 - -$0.44 | +14.58% | Beat | N/A | 7 | N/A | Nov 7, 2019 | $379000 |
| Jun 30, 2019 | -$0.47 | -$0.47 | -$0.55 - -$0.29 | 0.00% | In line | N/A | 8 | N/A | Aug 7, 2019 | $379000 |
| Mar 31, 2019 | -$0.53 | -$0.55 | -$0.61 - -$0.52 | +3.64% | Beat | N/A | 8 | N/A | May 6, 2019 | $379000 |
| Dec 31, 2018 | -$0.70 | -$0.67 | -$0.74 - -$0.63 | -4.48% | Miss | N/A | 8 | N/A | Mar 7, 2019 | $380000 |
| Sep 30, 2018 | -$0.68 | -$0.76 | -$0.94 - -$0.57 | +10.53% | Beat | N/A | 9 | N/A | Nov 5, 2018 | $379000 |
| Jun 30, 2018 | -$0.74 | -$0.89 | -$1.07 - -$0.82 | +16.85% | Beat | N/A | 9 | N/A | Aug 7, 2018 | $379000 |
| Mar 31, 2018 | -$0.79 | -$0.95 | -$1.20 - -$0.88 | +16.84% | Beat | N/A | 8 | N/A | May 8, 2018 | $379000 |
| Dec 31, 2017 | -$0.80 | -$0.78 | -$1.03 - -$0.61 | -2.56% | Miss | N/A | 8 | N/A | Mar 5, 2018 | $1.19M |
| Sep 30, 2017 | -$0.68 | -$0.82 | -$0.89 - -$0.74 | +17.07% | Beat | N/A | 8 | N/A | Nov 7, 2017 | $305000 |
| Jun 30, 2017 | -$0.70 | -$0.82 | -$0.91 - -$0.74 | +14.63% | Beat | N/A | 8 | N/A | Aug 10, 2017 | $305000 |
| Mar 31, 2017 | -$0.71 | -$0.71 | N/A | 0.00% | In line | N/A | N/A | N/A | May 8, 2017 | $305000 |
| Dec 31, 2016 | -$0.59 | -$0.73 | N/A | +19.18% | Beat | N/A | N/A | N/A | Mar 2, 2017 | $305000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.29, after -$3.73 the year before. It was -$2.63 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.29 | N/A |
| Dec 31, 2024 | -$3.73 | N/A |
| Dec 31, 2023 | -$2.96 | N/A |
| Dec 31, 2022 | -$2.45 | -669.8% |
| Dec 31, 2021 | $0.43 | N/A |
| Dec 31, 2020 | -$1.88 | N/A |
| Dec 31, 2019 | -$1.85 | N/A |
| Dec 31, 2018 | -$2.91 | N/A |
| Dec 31, 2017 | -$2.89 | N/A |
| Dec 31, 2016 | -$2.63 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 10,028 | 17 | |
| 2026Q2 | Jun 30, 2026 | 8,042 | 18 | |
| 2025Q4 | Dec 31, 2025 | 7,948 | 18 | |
| 2025Q3 | Sep 30, 2025 | 7,631 | 12 | |
| 2025Q2 | Jun 30, 2025 | 8,638 | 15 | |
| 2025Q1 | Mar 31, 2025 | 7,676 | 17 | |
| 2024Q4 | Dec 31, 2024 | 8,414 | 19 | |
| 2024Q3 | Sep 30, 2024 | 8,276 | 19 |
2026Q3 Earnings Call
Opening remarks
Sharon Klahre Head of Investor Relations Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's third quarter 2026 financial and operating results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Steven Closter, Chief Commercial Officer; Dr. Nick Botwood, Head of R&D and Chief Medical Officer; and Keith Goldan, Chief Financial Officer. This call is accompanied by a slide deck that has been posted on the Investor page of the company's website. You can now turn to our forward-looking statements on Slide 2. Before we begin, I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section in the company's most recent quarterly report on Form 10-Q, as well as other reports filed with the SEC. Any forward-looking statements made represent our views as of today, November 2nd, 2026, only. A replay of this call will be available on the company's website, www.syndax.com, following its completion. With that, I am pleased to turn the call over to Michael Metzger, Chief Executive Officer of Syndax.
Michael Metzger CEO Thank you, Sharon, and good afternoon, everyone. Let's start on Slide 3. Syndax delivered another strong quarter of commercial growth and pipeline momentum. Total revenue reached $83 million this quarter, up 82% year-over-year. Demand for both medicines is robust, and we are moving decisively towards profitability. Revuforj net revenue grew to $61 million in the third quarter, underscoring our market leadership in both relapsed/refractory NPM1 and KMT2A acute leukemia. Similar to prior quarters, we expect Revuforj to account for the vast majority, more than 80%, of the revenue for the class this quarter, a leading position we intend to carry forward. We achieved our seventh consecutive quarter of double-digit quarter-over-quarter Revuforj net revenue growth, driven by a 20% increase in new patients and an increasing number of patients resuming Revuforj after stem cell transplant. Notably, a growing number of both KMT2A and NPM1 patients are proceeding to transplant after receiving Revuforj. As patients pause treatment to receive a transplant, this creates a short-term headwind that will become a long-term tailwind as more patients resume therapy post-transplant, extending the average duration of therapy and driving durable growth for the franchise. Every indicator of Revuforj demand is positive. The latest data are clear.
Frequently Asked Questions About SNDX
When is Syndax Pharmaceuticals's next earnings date?
Syndax Pharmaceuticals's next earnings report is expected for Feb 24, 2027.
Did SNDX beat earnings estimates last quarter?
No. Syndax Pharmaceuticals reported EPS of -$0.55 for the quarter ended Sep 30, 2026, below the -$0.52 estimate by 5.77%.
What EPS do analysts expect from SNDX next quarter?
The consensus EPS estimate for Syndax Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.50 from 14 analysts, with estimates from -$0.59 to -$0.28.
How often does SNDX beat earnings estimates?
Syndax Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -46.21%.
SNDX pages: Overview, Earnings, Forecast, Financials, Competitors